Encouraging Results from MesomiR-1 Phase 1 Trial in Late Stage Mesothelioma patients

June 15, 2015

Dramatic Response with Novel microRNA Replacement Therapy in Malignant Pleural Mesothelioma Published in the American Journal of Respiratory and Critical Care Medicine NEW YORK and SYDNEY, June 15, 2015 /PRNewswire/ — EnGeneIC Ltd, an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced today that, together with the Asbestos Diseases […]

Read the full article →

3D Animation of MicroRNA biogenesis and functions

June 5, 2015

Ever had trouble explaining what you are doing? Now there is help… If you haven’t seen it on our Facebook page yet: Thanks go to Katharina Petsche who created a 3D medical animation about microRNAs‬ for her master graduation project. Very Cool!

Read the full article →

Regulus Initiates Phase I Clinical Study of RG-012, a microRNA Therapeutic in Development for the Treatment of Alport Syndrome

June 4, 2015

Achieves Key ‘Clinical Map Initiative’ Goal for 2015 and Advances Orphan Disease Efforts LA JOLLA, Calif., June 4, 2015 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically […]

Read the full article →

Workshop: microRNA Research & Immunology

May 7, 2015

If you are traveling to New Orleans to attend IMMUNOLOGY 2015 you might be interested in the following workshop next Monday, May 11th: Recent Work & Current Methods in Immunology microRNA Research May 11, 2015 – 11:15 AM-12:00 PM – Exhibit Hall Workshop Room #1 There is now strong evidence suggesting that miRNA signaling plays a […]

Read the full article →

Mirna Therapeutics Secures $41.8 Million Series D Financing to Advance Oncology MicroRNA Pipeline

April 30, 2015

Series D is Mirna’s Largest Financing to Date With Ten Institutional and Strategic Investors AUSTIN, TX–(Marketwired – April 30, 2015) – Mirna Therapeutics (Mirna), a private, clinical-stage biopharmaceutical and immuno-oncology company focused on the development of microRNA-based cancer therapeutics, today announced the completion of a $41.8 million Series D financing. The company’s second institutional financing was […]

Read the full article →

SomaGenics Awarded 2-Year NIH Grant to Develop NGS microRNA Library Technology

April 28, 2015

SANTA CRUZ, Calif., April 28, 2015 /PRNewswire/ — SomaGenics has been awarded a two-year NIH grant to develop its novel RealSeq™–T technology for targeted next-generation sequencing (NGS) of small RNAs such as microRNA. There is increasing interest in using NGS for miRNA biomarker discovery from biofluids such as blood plasma as well as for miRNA expression profiling and […]

Read the full article →

A microRNA Therapeutic Targeting microRNA-103/107 for the Treatment of NASH in Patients with Type 2 Diabetes/Pre-Diabetes, Selected as Clinical Candidate by AstraZeneca

April 7, 2015

-Regulus Earns $2.5 Million Milestone Payment from AstraZeneca- -RG-125 (AZD4076) is Regulus’ 3rd Clinical Candidate, Achieving Key ‘Clinical Map Initiative’ Goal for 2015- LA JOLLA, Calif., April 7, 2015 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR […]

Read the full article →

MicroRNA Therapeutic in Development Receives Orphan Medicinal Product Designation

March 25, 2015

Regulus Receives Orphan Medicinal Product Designation from the European Commission for RG-012, a microRNA Therapeutic in Development for the Treatment of Alport Syndrome LA JOLLA, Calif., March 25, 2015 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal […]

Read the full article →

Atheroprotective miRNA Signaling Pathways

January 22, 2015

MicroRNA (miRNA) are continually being identified as essential regulators of gene expression in a wide variety of different cellular contexts. A study published in March of 2012 in Nature Cell Biology1 identified an atheroprotective miRNA signaling pathway in which the miR-143/145 gene cluster is upregulated in endothelial cells and transferred to underlying smooth muscle cells […]

Read the full article →

Abcam acquires Firefly BioWorks to expand capabilities in multiplex analysis

January 22, 2015

Cambridge UK, 21 January, 2015: Abcam plc, a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire the entire issued share capital of Firefly BioWorks Inc (“Firefly”) (“the Acquisition”) on a cash-free/debt-free basis for £18.5m ($28.0m). The consideration, which is payable in […]

Read the full article →